REFERENCES
1. Müller F, Taubmann J, Bucci L, et al. CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up. N Engl J Med. 2024;390:687-700.
2. Wilhelm A, Chambers D, Müller F, et al. Selective CAR T cell-mediated B cell depletion suppresses IFN signature in SLE. JCI Insight. 2024;9:e179433.
3. Bertsias GK, Pamfil C, Fanouriakis A, Boumpas DT. Diagnostic criteria for systemic lupus erythematosus: has the time come? Nat Rev Rheumatol. 2013;9:687-94.
4. Mosca M, Costenbader KH, Johnson SR, et al. Brief report: how do patients with newly diagnosed systemic lupus erythematosus present? A multicenter cohort of early systemic lupus erythematosus to inform the development of new classification criteria. Arthritis Rheumatol. 2019;71:91-8.
5. Crow MK. Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets. Ann Rheum Dis. 2023;82:999-1014.
7. Piga M, Floris A, Sebastiani GD, et al. Risk factors of damage in early diagnosed systemic lupus erythematosus: results of the Italian multicentre early lupus project inception cohort. Rheumatology. 2020;59:2272-81.
8. Raman L, Yahya F, Ng CM, et al. Early damage as measured by SLICC/ACR damage index is a predictor of hospitalization in systemic lupus erythematosus (SLE). Lupus. 2020;29:1885-91.
9. Bournia VK, Fragoulis GE, Mitrou P, et al. Increased prevalence of inflammatory arthritis, systemic lupus erythematosus and systemic sclerosis, during 2020-2023 versus 2016-2019 in a Nation-Wide Cohort study. Rheumatol Int. 2024;44:2837-46.
10. Ellis J, McHugh N, Pauling JD, et al. Changes in the incidence and prevalence of systemic lupus erythematosus between 1990 and 2020: an observational study using the Clinical Practice Research Datalink (CPRD). Lupus Sci Med. 2024;11:e001213.
11. Ferrara P, Antonazzo IC, Zamparini M, et al. Epidemiology of SLE in Italy: an observational study using a primary care database. Lupus Sci Med. 2024;11:e001162.
12. Li M, Li C, Cao M, et al. Incidence and prevalence of systemic lupus erythematosus in urban China, 2013-2017: a nationwide population-based study. Sci Bull. 2024;69:3089-97.
13. Alexander T, Sewerin P, Strangfeld A, et al. Real-world prevalence, incidence and management of systemic lupus erythematosus in germany: a retrospective claims data analysis. Rheumatol Ther. 2025;12:237-54.
14. Etchegaray-Morales I, Mendoza-Pinto C, Arellano-Avendaño FJ, et al. Epidemiology of systemic lupus erythematosus in Latin America. Reumatol Clin. 2024;20:560-6.
15. Matsushita M, Sakai R, Yokogawa N, et al. Prevalence of systemic lupus erythematosus and age-stratified treatment trends in the Japanese population: a cross-sectional study based on the National Database of Health Insurance Claims. Mod Rheumatol. 2025:roaf020.
16. Müller F, Boeltz S, Knitza J, et al. CD19-targeted CAR T cells in refractory antisynthetase syndrome. Lancet. 2023;401:815-8.
17. Leuchten N, Milke B, Winkler-Rohlfing B, et al. Early symptoms of systemic lupus erythematosus (SLE) recalled by 339 SLE patients. Lupus. 2018;27:1431-6.
18. Leuchten N, Bauernfeind B, Kuttner J, et al. Relevant concepts of functioning for patients with systemic lupus erythematosus identified in a Delphi exercise of experts and a literature review. Arthritis Care Res. 2014;66:1895-904.
19. Bauernfeind B, Aringer M, Prodinger B, et al. Identification of relevant concepts of functioning in daily life in people with systemic lupus erythematosus: a patient Delphi exercise. Arthritis Rheum. 2009;61:21-8.
20. Almalag HM, Almaghlouth I, Dabbagh R, et al. Prevalence of fatigue functional and social impairment among patients with rheumatic diseases compared to patients without: a cross-sectional comparison. Medicine. 2023;102:e33151.
21. Doi H, Ohmura K, Hashimoto M, et al. Factors affecting discrepancies in disease activity evaluation between patients and physicians in systemic lupus erythematosus-The importance of symptoms such as fatigue. Lupus. 2024;33:1336-44.
22. Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American college of rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 2019;71:1400-12.
23. Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78:1151-9.
24. Aringer M, Brinks R, Dörner T, et al. European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. Ann Rheum Dis. 2021;80:775-81.
25. Tedeschi SK, Johnson SR, Boumpas D, et al. Developing and refining new candidate criteria for systemic lupus erythematosus classification: an international collaboration. Arthritis Care Res. 2018;70:571-81.
26. Aringer M, Johnson SR. Classifying and diagnosing systemic lupus erythematosus in the 21st century. Rheumatology. 2020;59:v4-11.
27. Petri M, Orbai AM, Alarcon GS, et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64:2677-86.
28. Touma Z, Cervera R, Brinks R, et al. Associations between classification criteria items in systemic lupus erythematosus. Arthritis Care Res. 2020;72:1820-6.
29. Mosca M, Tani C, Aringer M, et al. Development of quality indicators to evaluate the monitoring of SLE patients in routine clinical practice. Autoimmun Rev. 2011;10:383-8.
31. Leuchten N, Hoyer A, Brinks R, et al. Performance of antinuclear antibodies for classifying systemic lupus erythematosus: a systematic literature review and meta-regression of diagnostic data. Arthritis Care Res. 2018;70:428-38.
32. Aringer M, Johnson SR. Systemic lupus erythematosus classification and diagnosis. Rheum Dis Clin North Am. 2021;47:501-11.
33. Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH. Assay variation in the detection of antinuclear antibodies in the sera of patients with established SLE. Ann Rheum Dis. 2018;77:911-3.
34. Jeong S, Yang D, Lee W, et al. Diagnostic value of screening enzyme immunoassays compared to indirect immunofluorescence for anti-nuclear antibodies in patients with systemic rheumatic diseases: a systematic review and meta-analysis. Semin Arthritis Rheum. 2018;48:334-42.
35. Livingston B, Bonner A, Pope J. Differences in autoantibody profiles and disease activity and damage scores between childhood- and adult-onset systemic lupus erythematosus: a meta-analysis. Semin Arthritis Rheum. 2012;42:271-80.
36. Agmon-Levin N, Damoiseaux J, Kallenberg C, Sack U, Witte T, et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis. 2014;73:17-23.
37. Infantino M, Manfredi M, Merone M, et al. Analytical variability in the determination of anti-double-stranded DNA antibodies: the strong need of a better definition of the old and new tests. Immunol Res. 2018;66:340-7.
38. Infantino M, Palterer B, Previtali G, et al. Comparison of current methods for anti-dsDNA antibody detection and reshaping diagnostic strategies. Scand J Immunol. 2022;96:e13220.
39. Infantino M, Nagy E, Bizzaro N, Fischer K, Bossuyt X, Damoiseaux J. Anti-dsDNA antibodies in the classification criteria of systemic lupus erythematosus. J Transl Autoimmun. 2022;5:100139.
40. Trujillo Aguilera A, Bernardo Serrano R, Navas A, et al. Longitudinal study of patients with discrepant results in CLIFT and a solid-phase dsDNA antibody assay: does a gold standard dsDNA assay exist? Lupus Sci Med. 2023;10:e000984.
41. Mummert E, Fritzler MJ, Sjöwall C, Bentow C, Mahler M. The clinical utility of anti-double-stranded DNA antibodies and the challenges of their determination. J Immunol Methods. 2018;459:11-9.
42. Ramsey-Goldman R, Alexander RV, Massarotti EM, et al. Complement activation in patients with probable systemic lupus erythematosus and ability to predict progression to american college of rheumatology-classified systemic lupus erythematosus. Arthritis Rheumatol. 2020;72:78-88.
43. Crow MK, Olferiev M, Kirou KA. Standing on shoulders: interferon research from viral interference to lupus pathogenesis and treatment. Arthritis Rheumatol. 2024;76:1002-12.
44. Aringer M, Dörner T, Leuchten N, Johnson SR. Toward new criteria for systemic lupus erythematosus-a standpoint. Lupus. 2016;25:805-11.
45. Johnson SR, Goek ON, Singh-Grewal D, et al. Classification criteria in rheumatic diseases: a review of methodologic properties. Arthritis Rheum. 2007;57:1119-33.
46. Piga M, Tselios K, Viveiros L, et al. Clinical patterns of disease: from early systemic lupus erythematosus to late-onset disease. Best Pract Res Clin Rheumatol. 2023;37:101938.
47. Riveros Frutos A, Holgado S, Sanvisens Bergé A, et al. Late-onset versus early-onset systemic lupus: characteristics and outcome in a national multicentre register (RELESSER). Rheumatology. 2021;60:1793-803.
48. Viveiros L, Neves A, Gouveia T, Isenberg DA. A large cohort comparison of very late-onset systemic lupus erythematosus with younger-onset patients. Clin Exp Rheumatol. 2024;42:1480-6.
49. Sakurai N, Yoshimi R, Yajima N, et al. Characteristic features of late-onset systemic lupus erythematosus: An observational study of data from the Lupus Registry of Nationwide Institutions. Lupus. 2024;33:1306-16.
50. Adamichou C, Genitsaridi I, Nikolopoulos D, et al. Lupus or not? SLE risk probability index (SLERPI): a simple, clinician-friendly machine learning-based model to assist the diagnosis of systemic lupus erythematosus. Ann Rheum Dis. 2021;80:758-66.
51. Hammam N, Elsaman A, Abualfadl E, et al. Performance of the systemic lupus erythematosus risk probability index (SLERPI) in the Egyptian college of rheumatology (ECR) study cohort. Clin Rheumatol. 2025;44:207-15.
52. Celis-Andrade M, Rojas M, Rodríguez Y, et al. Performance of the systemic lupus erythematosus risk probability index (SLERPI) in a cohort of Colombian population. Clin Rheumatol. 2024;43:3313-22.
53. Zhang L, Lu W, Yan D, Liu Z, Xue L. Systemic lupus erythematosus risk probability index: ready for routine use? Results from a Chinese cohort. Lupus Sci Med. 2023:10.
54. Kapsala N, Nikolopoulos D, Flouda S, et al. First diagnosis of systemic lupus erythematosus in hospitalized patients: clinical phenotypes and pitfalls for the Non-specialist. Am J Med. 2022;135:244-53.e3.
55. Munguía-Realpozo P, Etchegaray-Morales I, Mendoza-Pinto C, et al. Current state and completeness of reporting clinical prediction models using machine learning in systemic lupus erythematosus: a systematic review. Autoimmun Rev. 2023;22:103294.
56. Johnson SR, Alahmari H, Bonilla D, et al. Evaluation of progression from preclinical to systemic autoimmune rheumatic disease: novel use of the European Alliance of Associations for Rheumatology/American College of Rheumatology systemic lupus erythematosus classification criteria as an outcome measure. ACR Open Rheumatol. 2024;6:871-7.
57. Winthrop KL, Strand V, van der Heijde D, et al. The unmet need in rheumatology: reports from the targeted therapies meeting 2017. Clin Immunol. 2018;186:87-93.
58. Munroe ME, Young KA, Guthridge JM, et al. Pre-Clinical autoimmunity in lupus relatives: self-reported questionnaires and immune dysregulation distinguish relatives who develop incomplete or classified lupus from clinically unaffected relatives and unaffected, unrelated individuals. Front Immunol. 2022;13:866181.
59. Ghodke-Puranik Y, Olferiev M, Crow MK. Systemic lupus erythematosus genetics: insights into pathogenesis and implications for therapy. Nat Rev Rheumatol. 2024;20:635-48.
60. Rodríguez RD, Alarcón-Riquelme ME. Exploring the contribution of genetics on the clinical manifestations of systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2024;38:101971.
61. Hiraki LT, Silverman ED. Genomics of systemic lupus erythematosus: insights gained by studying monogenic young-onset systemic lupus erythematosus. Rheum Dis Clin North Am. 2017;43:415-34.
62. Guga S, Wang Y, Graham DC, Vyse TJ. A review of genetic risk in systemic lupus erythematosus. Expert Rev Clin Immunol. 2023;19:1247-58.
63. Grennan DM, Parfitt A, Manolios N, et al. Family and twin studies in systemic lupus erythematosus. Dis Markers. 1997;13:93-8.
64. Lundtoft C, Sjöwall C, Rantapää-Dahlqvist S, et al. Strong association of combined genetic deficiencies in the classical complement pathway with risk of systemic lupus erythematosus and primary sjögren's syndrome. Arthritis Rheumatol. 2022;74:1842-50.
65. Truedsson L. Classical pathway deficiencies - a hort analytical review. Mol Immunol. 2015;68:14-9.
66. Ramantani G, Kohlhase J, Hertzberg C, et al. Expanding the phenotypic spectrum of lupus erythematosus in Aicardi-Goutieres syndrome. Arthritis Rheum. 2010;62:1469-77.
67. Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349:1526-33.
68. Hedlund M, Thorlacius GE, Ivanchenko M, et al. Type I IFN system activation in newborns exposed to Ro/SSA and La/SSB autoantibodies in utero. RMD Open. 2020;6:e000989.
